Your browser doesn't support javascript.
loading
A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers.
Starks, David; Rojas-Espaillat, Luis; Meissner, Tobias; Elsey, Rachel; Xu, Bing; Koenen, Maria; Feng, Shelley; VanOosbree, Annika; Slunecka, John; Lee, John; Williams, Casey B.
Afiliación
  • Starks D; Avera Cancer Institute, Sioux Falls, South Dakota, USA.
  • Rojas-Espaillat L; Avera Cancer Institute, Sioux Falls, South Dakota, USA.
  • Meissner T; Avera Cancer Institute, Sioux Falls, South Dakota, USA.
  • Elsey R; Avera Cancer Institute, Sioux Falls, South Dakota, USA.
  • Xu B; Avera Cancer Institute, Sioux Falls, South Dakota, USA.
  • Koenen M; University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.
  • Feng S; University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.
  • VanOosbree A; University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.
  • Slunecka J; University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.
  • Lee J; Avera Cancer Institute, Sioux Falls, South Dakota, USA.
  • Williams CB; Avera Cancer Institute, Sioux Falls, South Dakota, USA.
Cancer Med ; 12(18): 18654-18665, 2023 Sep.
Article en En | MEDLINE | ID: mdl-37644890
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos